Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Zestra Laboratories has begun enrollment in a National Institutes of Health registered phase III-type clinical study of its commercially available non-prescription product, Zestra feminine arousal fluid.
Subscribe to our email newsletter
According to the company, Zestra is the only consumer product available that is clinically shown to quickly increase female sexual sensation, arousal, pleasure, and improve sexual experiences for women.
This phase III-type study is evaluating the efficacy and safety of Zestra compared to placebo oil in 200 women diagnosed with acquired mixed sexual disorders in conditions of home use in conjunction with sexual activities. The Zestra study is the only NIH-registered study to directly address women’s sexual problems.
Primary efficacy assessment will be the subjects’ assessments of “successful and satisfactory” sexual encounters as recorded in a diary. Secondary evaluations of efficacy will include a subject self-assessment questionnaires, sexual encounter frequency and drop-out rates.